<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>338</serviceExecutionTime><Drug id="7595"><DrugName>interleukin-1 receptor gene therapy, Theragen</DrugName><DrugSynonyms><Name><Value>IL-1 receptor gene therapy, Theragen</Value></Name><Name><Value>interleukin-1 receptor gene therapy, Theragen</Value></Name></DrugSynonyms><CompanyOriginator id="20509">Theragen Inc</CompanyOriginator><CompaniesSecondary><Company id="20509">Theragen Inc</Company><Company id="20787">Warner-Lambert Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20509" type="Company"><TargetEntity id="4296599700" type="organizationId">Theragen Inc</TargetEntity></SourceEntity><SourceEntity id="20787" type="Company"><TargetEntity id="5000822663" type="organizationId">Warner Lambert Co</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3044" type="Action"><TargetEntity id="1959" type="Mechanism">IL-1 Receptor Ligands</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="3044">IL-1 receptor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="4792">Unspecified vector based gene therapy</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="160">Vector expression</Technology></Technologies><LastModificationDate>2017-09-01T09:47:27.000Z</LastModificationDate><ChangeDateLast>2008-09-02T12:43:30.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Theragen was developing an interleukin-1 receptor (IL-1r) gene therapy for the potential treatment of rheumatoid arthritis [&lt;ulink linkID="158040" linkType="reference"&gt;158040&lt;/ulink&gt;], however since the company buy out by GenVec, all arthritis research has been dropped [&lt;ulink linkID="244388" linkType="reference"&gt;244388&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><Source id="244388" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20509">Theragen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><Source id="244388" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20787">Warner-Lambert Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="158040" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20509">Theragen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="158040" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00982"><Name>IL-1 receptor</Name><SwissprotNumbers><Swissprot>P13504</Swissprot><Swissprot>P14778</Swissprot><Swissprot>P27930</Swissprot><Swissprot>P27931</Swissprot><Swissprot>P43303</Swissprot><Swissprot>Q02955</Swissprot><Swissprot>Q29612</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1021778">Intrexon Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="115442" title="Warner-Lambert to develop Theragen's gene therapy products"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>